Medicus Pharma (MDCX) EPS (Basic) (2024 - 2026)
Medicus Pharma's (MDCX) quarterly EPS (Basic) came in at -$0.87 in Q4 2025, down 137.11% YoY from $2.35 in Q4 2024, and down 6220.37% on a QoQ basis from -$0.01 in Q3 2025.
Medicus Pharma (MDCX) EPS (Basic) (2024 - 2026) Analysis & Trends
Medicus Pharma (MDCX) has 2 years of EPS (Basic) data on file, last reported at -$0.87 in Q4 2025.
- Quarterly EPS (Basic) fell 137.11% year-over-year to -$0.87 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.57 (down 35.98% YoY) and the FY2025 annual result came in at -$2.74, down 135.89% from the prior year.
- EPS (Basic) retreated to -$0.87 in Q4 2025, from -$0.01 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.01 in Q3 2025 to a low of -$0.87 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.30 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 2.04 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -0.54 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.71 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.62 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 4.40 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -8.44 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -0.04 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 0.29 |
| 10 | Medicus Pharma | 14.88 Mn | -298,205.43 | - | -0.21 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.68 |
| Dec 31, 2025 | -0.87 |
| Sep 30, 2025 | -0.01 |
| Jun 30, 2025 | -0.44 |
| Mar 31, 2025 | -0.44 |
| Dec 31, 2024 | -0.37 |
| Sep 30, 2024 | -0.24 |
| Jun 30, 2024 | -0.44 |
| Mar 31, 2024 | -0.21 |